Newer antibiotics for serious gram-positive infections

Article Type
Changed
Wed, 08/22/2018 - 10:09
Display Headline
Newer antibiotics for serious gram-positive infections
Article PDF
Author and Disclosure Information

Thomas G. Fraser, MD
Department of Infectious Diseases, Cleveland Clinic

Christine Hansen, PharmD
Department of Pharmacy, Shands Hospital, Orlando, FL

Jennifer K. Long, PharmD
Department of Pharmacy, Cleveland Clinic

Address: Thomas G. Fraser, MD, Department of Infectious Disease, S32, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail frasert@ccf.org

Dr. Fraser is a member of the Wyeth Emerging Pathogens speakers’ bureau.

Dr. Long is a member of the Cubist speakers’ bureau and the Pfizer speakers’ bureau. This manuscript was generated without outside funding.

Issue
Cleveland Clinic Journal of Medicine - 73(9)
Publications
Topics
Page Number
847-853
Sections
Author and Disclosure Information

Thomas G. Fraser, MD
Department of Infectious Diseases, Cleveland Clinic

Christine Hansen, PharmD
Department of Pharmacy, Shands Hospital, Orlando, FL

Jennifer K. Long, PharmD
Department of Pharmacy, Cleveland Clinic

Address: Thomas G. Fraser, MD, Department of Infectious Disease, S32, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail frasert@ccf.org

Dr. Fraser is a member of the Wyeth Emerging Pathogens speakers’ bureau.

Dr. Long is a member of the Cubist speakers’ bureau and the Pfizer speakers’ bureau. This manuscript was generated without outside funding.

Author and Disclosure Information

Thomas G. Fraser, MD
Department of Infectious Diseases, Cleveland Clinic

Christine Hansen, PharmD
Department of Pharmacy, Shands Hospital, Orlando, FL

Jennifer K. Long, PharmD
Department of Pharmacy, Cleveland Clinic

Address: Thomas G. Fraser, MD, Department of Infectious Disease, S32, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail frasert@ccf.org

Dr. Fraser is a member of the Wyeth Emerging Pathogens speakers’ bureau.

Dr. Long is a member of the Cubist speakers’ bureau and the Pfizer speakers’ bureau. This manuscript was generated without outside funding.

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 73(9)
Issue
Cleveland Clinic Journal of Medicine - 73(9)
Page Number
847-853
Page Number
847-853
Publications
Publications
Topics
Article Type
Display Headline
Newer antibiotics for serious gram-positive infections
Display Headline
Newer antibiotics for serious gram-positive infections
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

From principles to practice: Case-based applications of the acute otitis media guidelines

Article Type
Changed
Tue, 10/23/2018 - 08:38
Display Headline
From principles to practice: Case-based applications of the acute otitis media guidelines
Article PDF
Author and Disclosure Information

Camille Sabella, MD
Staff, Section of Pediatric Infectious Diseases, The Children’s Hospital, Cleveland Clinic Foundation; Associate Professor of Pediatrics, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio

Johanna Goldfarb, MD
Section Head, Pediatric Infectious Diseases, The Children’s Hospital, Cleveland Clinic Foundation, Cleveland, Ohio

Scott Francy, MD
Staff, Department of General Pediatrics, The Children’s Hospital, Cleveland Clinic Foundation, Cleveland, Ohio

Jennifer K. Long, PharmD
Infectious Diseases Clinical Pharmacy Specialist, Department of Pharmacy, Cleveland Clinic Foundation, Cleveland, Ohio

S. Michael Marcy, MD
Clinical Professor of Pediatrics, University of Southern California and University of California, Los Angeles, Schools of Medicine, Los Angeles, and Kaiser Foundation Hospital, Panorama City, Calif.; Consultant, American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media

Jennifer K. Long, PharmD, reported that she is on the speakers’ bureaus of the Bayer and Pfizer corporations.

S. Michael Marcy, MD, reported that he serves as a consultant to the Abbott and GlaxoSmithKline corporations. He also reported that he discusses off-label uses of therapies.

Scott Francy, MD, Johanna Goldfarb, MD, and Camille Sabella, MD, reported no relationships that could be perceived as a conflict of interest.

Publications
Page Number
S10-S18
Author and Disclosure Information

Camille Sabella, MD
Staff, Section of Pediatric Infectious Diseases, The Children’s Hospital, Cleveland Clinic Foundation; Associate Professor of Pediatrics, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio

Johanna Goldfarb, MD
Section Head, Pediatric Infectious Diseases, The Children’s Hospital, Cleveland Clinic Foundation, Cleveland, Ohio

Scott Francy, MD
Staff, Department of General Pediatrics, The Children’s Hospital, Cleveland Clinic Foundation, Cleveland, Ohio

Jennifer K. Long, PharmD
Infectious Diseases Clinical Pharmacy Specialist, Department of Pharmacy, Cleveland Clinic Foundation, Cleveland, Ohio

S. Michael Marcy, MD
Clinical Professor of Pediatrics, University of Southern California and University of California, Los Angeles, Schools of Medicine, Los Angeles, and Kaiser Foundation Hospital, Panorama City, Calif.; Consultant, American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media

Jennifer K. Long, PharmD, reported that she is on the speakers’ bureaus of the Bayer and Pfizer corporations.

S. Michael Marcy, MD, reported that he serves as a consultant to the Abbott and GlaxoSmithKline corporations. He also reported that he discusses off-label uses of therapies.

Scott Francy, MD, Johanna Goldfarb, MD, and Camille Sabella, MD, reported no relationships that could be perceived as a conflict of interest.

Author and Disclosure Information

Camille Sabella, MD
Staff, Section of Pediatric Infectious Diseases, The Children’s Hospital, Cleveland Clinic Foundation; Associate Professor of Pediatrics, Cleveland Clinic Lerner College of Medicine, Cleveland, Ohio

Johanna Goldfarb, MD
Section Head, Pediatric Infectious Diseases, The Children’s Hospital, Cleveland Clinic Foundation, Cleveland, Ohio

Scott Francy, MD
Staff, Department of General Pediatrics, The Children’s Hospital, Cleveland Clinic Foundation, Cleveland, Ohio

Jennifer K. Long, PharmD
Infectious Diseases Clinical Pharmacy Specialist, Department of Pharmacy, Cleveland Clinic Foundation, Cleveland, Ohio

S. Michael Marcy, MD
Clinical Professor of Pediatrics, University of Southern California and University of California, Los Angeles, Schools of Medicine, Los Angeles, and Kaiser Foundation Hospital, Panorama City, Calif.; Consultant, American Academy of Pediatrics Subcommittee on Management of Acute Otitis Media

Jennifer K. Long, PharmD, reported that she is on the speakers’ bureaus of the Bayer and Pfizer corporations.

S. Michael Marcy, MD, reported that he serves as a consultant to the Abbott and GlaxoSmithKline corporations. He also reported that he discusses off-label uses of therapies.

Scott Francy, MD, Johanna Goldfarb, MD, and Camille Sabella, MD, reported no relationships that could be perceived as a conflict of interest.

Article PDF
Article PDF
Related Articles
Page Number
S10-S18
Page Number
S10-S18
Publications
Publications
Article Type
Display Headline
From principles to practice: Case-based applications of the acute otitis media guidelines
Display Headline
From principles to practice: Case-based applications of the acute otitis media guidelines
Citation Override
Cleveland Clinic Journal of Medicine 2004 June;71(suppl 4):S10-S18
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Antiviral agents for treating influenza

Article Type
Changed
Mon, 02/04/2019 - 10:18
Display Headline
Antiviral agents for treating influenza
Article PDF
Author and Disclosure Information

Jennifer K. Long, PharmD
Department of Pharmacy, Cleveland Clinic

Sherif B. Mossad, MD
Department of Infectious Diseases, Cleveland Clinic

Morton P. Goldman, PharmD
Department of Pharmacy, Cleveland Clinic

Dr. Mossad serves on the speakers' bureau of Roche Pharmaceuticals (which makes oseltamivir).

Dr. Goldman serves on the speakers' bureau of Roche Pharmaceuticals and Glaxo Wellcome Inc. (which makes zanamivir).

Issue
Cleveland Clinic Journal of Medicine - 67(2)
Publications
Topics
Page Number
92-95
Sections
Author and Disclosure Information

Jennifer K. Long, PharmD
Department of Pharmacy, Cleveland Clinic

Sherif B. Mossad, MD
Department of Infectious Diseases, Cleveland Clinic

Morton P. Goldman, PharmD
Department of Pharmacy, Cleveland Clinic

Dr. Mossad serves on the speakers' bureau of Roche Pharmaceuticals (which makes oseltamivir).

Dr. Goldman serves on the speakers' bureau of Roche Pharmaceuticals and Glaxo Wellcome Inc. (which makes zanamivir).

Author and Disclosure Information

Jennifer K. Long, PharmD
Department of Pharmacy, Cleveland Clinic

Sherif B. Mossad, MD
Department of Infectious Diseases, Cleveland Clinic

Morton P. Goldman, PharmD
Department of Pharmacy, Cleveland Clinic

Dr. Mossad serves on the speakers' bureau of Roche Pharmaceuticals (which makes oseltamivir).

Dr. Goldman serves on the speakers' bureau of Roche Pharmaceuticals and Glaxo Wellcome Inc. (which makes zanamivir).

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 67(2)
Issue
Cleveland Clinic Journal of Medicine - 67(2)
Page Number
92-95
Page Number
92-95
Publications
Publications
Topics
Article Type
Display Headline
Antiviral agents for treating influenza
Display Headline
Antiviral agents for treating influenza
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media